Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.02Last Year’s EPS
-0.02Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -1.15%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with notable revenue growth and strategic acquisitions offset by a decline in adjusted EBITDA, financial asset losses, and increased operating expenses. While there are promising developments in the promoted portfolio and upcoming product launches, financial challenges need to be addressed.Company Guidance
During Knight Therapeutics' first-quarter 2025 conference call, the company reported revenues of $88 million, marking a 3% year-over-year increase, primarily driven by a 16% growth in their promoted portfolio. Adjusted EBITDA stood at over $12 million, with a decrease of 11% from the previous year. The oncology and hematology portfolio contributed $32 million, growing by 3%, while the infectious disease portfolio reported $36 million, a 4% decline. Knight also highlighted significant transactions, including the $100 million acquisition of Paladin's assets and the expansion with Helsinn to include Onicit in specific Latin American markets. Financial guidance for fiscal 2025 anticipates revenues between $390 million and $405 million, with an adjusted EBITDA margin of approximately 13%. The company also executed a share buyback under the NCIB and secured a $40 million line of credit to support their financial strategy.Revenue Growth
Knight Therapeutics reported revenues of $88 million for Q1 2025, an increase of $2 million or 3% over the same period last year.
Promoted Portfolio Performance
The promoted portfolio, accounting for over 75% of total revenues, grew by $9 million or 16% on a constant currency basis.
Oncology and Hematology Portfolio Growth
This portfolio delivered $32 million in revenues, a growth of $1 million or 3%, and $2 million or 6% on a constant currency basis.
Infectious Disease Portfolio Growth on Constant Currency
Despite a nominal decrease, the portfolio grew by $1 million or 3% on a constant currency basis.
Pipeline and Product Launches
Knight continued to advance its portfolio with regulatory submissions and approvals, launching Minjuvi in Mexico and relaunching Onicit in Brazil and Mexico.
Paladin Acquisition
Knight entered into an agreement to acquire the assets of Paladin for $100 million plus $20 million of inventory, with potential future contingent payments up to $15 million.
Financial Outlook for 2025
Knight expects to generate revenues between $390 million to $405 million and an adjusted EBITDA of approximately 13% of revenues.
TSE:GUD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:GUD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | C$6.07 | C$5.68 | -6.43% |
Mar 20, 2025 | C$6.25 | C$6.27 | +0.32% |
Nov 07, 2024 | C$5.74 | C$5.15 | -10.28% |
Aug 08, 2024 | C$5.54 | C$5.76 | +3.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Knight Therapeutics (TSE:GUD) report earnings?
Knight Therapeutics (TSE:GUD) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Knight Therapeutics (TSE:GUD) earnings time?
Knight Therapeutics (TSE:GUD) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:GUD EPS forecast?
TSE:GUD EPS forecast for the fiscal quarter 2025 (Q2) is 0.02.